These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 20587123

  • 21. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R, Svensson E, Trollfors B, Borres MP.
    Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890
    [Abstract] [Full Text] [Related]

  • 22. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z, Yan R, He H, Li Q, Chen G, Yang S, Chen E.
    PLoS One; 2014 Sep; 9(2):e89361. PubMed ID: 24586717
    [Abstract] [Full Text] [Related]

  • 23. MMR vaccination and disease elimination: the Finnish experience.
    Davidkin I, Kontio M, Paunio M, Peltola H.
    Expert Rev Vaccines; 2010 Sep; 9(9):1045-53. PubMed ID: 20822347
    [Abstract] [Full Text] [Related]

  • 24. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S.
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [Abstract] [Full Text] [Related]

  • 25. Adolescent immunizations: missed opportunities for prevention.
    Lee GM, Lorick SA, Pfoh E, Kleinman K, Fishbein D.
    Pediatrics; 2008 Oct; 122(4):711-7. PubMed ID: 18829792
    [Abstract] [Full Text] [Related]

  • 26. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Jun 14; 62(RR-04):1-34. PubMed ID: 23760231
    [Abstract] [Full Text] [Related]

  • 27. Type 1 diabetes and measles, mumps and rubella childhood infections within the Italian Insulin-dependent Diabetes Registry.
    Ramondetti F, Sacco S, Comelli M, Bruno G, Falorni A, Iannilli A, d'Annunzio G, Iafusco D, Songini M, Toni S, Cherubini V, Carle F, RIDI Study Group.
    Diabet Med; 2012 Jun 14; 29(6):761-6. PubMed ID: 22133003
    [Abstract] [Full Text] [Related]

  • 28. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
    Sáenz González MC, Núñez Mateos JC, Rodrigo Sánchez N, Martín Sánchez AM.
    An Esp Pediatr; 1992 Apr 14; 36(4):293-7. PubMed ID: 1605414
    [Abstract] [Full Text] [Related]

  • 29. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
    Gohil DJ, Kothari ST, Chaudhari AB, Gunale BK, Kulkarni PS, Deshmukh RA, Chowdhary AS.
    Viral Immunol; 2016 Apr 14; 29(3):159-63. PubMed ID: 26910764
    [Abstract] [Full Text] [Related]

  • 30. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, Cantell K.
    N Engl J Med; 1994 Nov 24; 331(21):1397-402. PubMed ID: 7969278
    [Abstract] [Full Text] [Related]

  • 31. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F, Santoli J, Messonnier ML, Yusuf HR, Shefer A, Chu SY, Rodewald L, Harpaz R.
    Arch Pediatr Adolesc Med; 2005 Dec 24; 159(12):1136-44. PubMed ID: 16330737
    [Abstract] [Full Text] [Related]

  • 32. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.
    Cassidy WM, Jones G, Williams K, Deforest A, Forghani B, Virella G, Venters C.
    J Adolesc Health; 2005 Mar 24; 36(3):187-92. PubMed ID: 15737773
    [Abstract] [Full Text] [Related]

  • 33. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
    Leuridan E, Maertens K, Wautier M, Hutse V, Theeten H.
    Eur J Pediatr; 2015 Jul 24; 174(7):925-32. PubMed ID: 25579232
    [Abstract] [Full Text] [Related]

  • 34. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.
    J Infect Dis; 2008 Apr 01; 197(7):950-6. PubMed ID: 18419470
    [Abstract] [Full Text] [Related]

  • 35. Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II.
    Knutsson N, Jansson UB, Alm B.
    Vaccine; 2006 Jul 26; 24(31-32):5800-5. PubMed ID: 16765490
    [Abstract] [Full Text] [Related]

  • 36. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity.
    Kim SS, Han HW, Go U, Chung HW.
    Vaccine; 2004 Dec 02; 23(3):290-7. PubMed ID: 15530670
    [Abstract] [Full Text] [Related]

  • 37. Update: childhood vaccine-preventable diseases--United States, 1994.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1994 Oct 07; 43(39):718-20. PubMed ID: 8090160
    [Abstract] [Full Text] [Related]

  • 38. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
    Plans P, de Ory F, Campins M, Álvarez E, Payà T, Guisasola E, Compte C, Vellbé K, Sánchez C, Lozano MJ, Aran I, Bonmatí A, Carreras R, Jané M, Cabero L.
    Eur J Clin Microbiol Infect Dis; 2015 Jun 07; 34(6):1161-71. PubMed ID: 25666082
    [Abstract] [Full Text] [Related]

  • 39. Reported vaccine-preventable diseases--United States, 1993, and the childhood immunization initiative.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1994 Feb 04; 43(4):57-60. PubMed ID: 8295625
    [Abstract] [Full Text] [Related]

  • 40. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL, Bennett JV, Castaneda D, Vieyra JR, Valdespino-Gomez JL, de Castro JF.
    Vaccine; 2010 Jan 08; 28(3):692-8. PubMed ID: 19861187
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.